




RealRate

PHARMACEUTICAL 2021

ADIAL PHARMACEUTICALS INC.
Rank 393 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

ADIAL PHARMACEUTICALS INC. Rank 393 of 409

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 89% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 690% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,139%, being 784% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	5,136
Cost of Goods Sold	0
Intangible Assets	5.6
Liabilities, Current	1,505
Liabilities, Non-Current	0
Other Assets	350
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	35
Property and Equipment	0
Research and Development	5,853
Revenues	0
Selling, General and Administrative Expense	5,075

Output Variable	Value in 1000 USD
Assets	5,491
Liabilities	1,505
Expenses	10,928
Stockholders Equity	3,986
Net Income	-10,893
Comprehensive Net Income	-10,893
Economic Capital Ratio	-1,139%

